These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 8191968)

  • 1. [Clinical evaluation of M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapy for advanced urothelial cancer].
    Mikami K; Nakagawa S; Takada H; Ebisui K; Sugimoto K; Watanabe H; Maegawa M; Nakao M
    Hinyokika Kiyo; 1994 Apr; 40(4):303-7. PubMed ID: 8191968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapy in advanced renal pelvic and ureteral carcinoma].
    Igawa M; Ueki T; Ueda M; Okada K; Usui T; Ohnishi Y; Kume T; Masu C; Ishino T; Nakatsu H
    Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2577-82. PubMed ID: 2673046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Combination chemotherapy with M-VAC protocol in metastatic urothelial cancer].
    Sella A; Flex D; Gafni D; Rabinovitz O; Sulkes A; Baniel J
    Harefuah; 1999 Feb; 136(4):268-71, 340, 339. PubMed ID: 10914214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [M-VAC chemotherapy for advanced urothelial cancer--side effects and their management].
    Noguchi S; Kubota Y; Shuin T; Masuda M; Misaki H; Yao M; Kondoh K; Sakuramoto T; Hosaka M
    Hinyokika Kiyo; 1994 Aug; 40(8):677-82. PubMed ID: 7942364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical and pathological evaluations of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) chemotherapy for advanced urothelial cancers].
    Takenaka A; Gotoh A; Hara I; Gohji K; Ogawa T; Arakawa S; Matsumoto O; Kamidono S; Hamami G; Itani A
    Gan To Kagaku Ryoho; 1990 Sep; 17(9):1909-15. PubMed ID: 2393308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma.
    Soga N; Arima K; Sugimura Y
    Int J Urol; 2008 Sep; 15(9):800-3. PubMed ID: 18651862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can patient selection for bladder preservation be based on response to chemotherapy?
    Sternberg CN; Pansadoro V; Calabrò F; Schnetzer S; Giannarelli D; Emiliozzi P; De Paula F; Scarpone P; De Carli P; Pizzo M; Platania A; Amini M
    Cancer; 2003 Apr; 97(7):1644-52. PubMed ID: 12655521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical study of modified M-VAC therapy with one 21-day cycle for advanced urothelial cancer].
    Nakanishi S; Matsuzaki M; Morikawa H; Nakano M; Komatsu H
    Hinyokika Kiyo; 2004 Oct; 50(10):667-71. PubMed ID: 15575216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck.
    Okuno SH; Mailliard JA; Suman VJ; Edmonson JH; Creagan ET; Nair S; Levitt R; Kugler JW
    Cancer; 2002 Apr; 94(8):2224-31. PubMed ID: 12001121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Experience with combination chemotherapy consisting of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial cancer].
    Nishio Y; Shirahase T; Shichiri Y; Habuchi T; Matsuda T; Nishimura K; Hida S; Okada Y; Yoshida O
    Hinyokika Kiyo; 1988 Aug; 34(8):1371-5. PubMed ID: 3195405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for poor prognosis patients with urothelial tumors and effect of dose intensity.
    Hibi H; Okamura K; Takashi M; Shimoji T; Miyake K
    Hinyokika Kiyo; 1997 Feb; 43(2):89-96. PubMed ID: 9086342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer.
    Siefker-Radtke AO; Millikan RE; Tu SM; Moore DF; Smith TL; Williams D; Logothetis CJ
    J Clin Oncol; 2002 Mar; 20(5):1361-7. PubMed ID: 11870180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [MEP (methotrexate, etoposide and cisplatin) and M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced uroepithelial cancer--a preliminary report of MEP as second line chemotherapy for recurrence after M-VAC].
    Seguchi T; Nakano E; Miki T; Kondoh M; Nishimura K; Nakamura N; Okuyama A
    Gan To Kagaku Ryoho; 1994 Jan; 21(1):59-65. PubMed ID: 8291917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of dose intensity on M-VAC therapy for advanced urothelial cancer.
    Miyanaga N; Akaza H; Shimazui T; Ohtani M; Koiso K
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S5-8. PubMed ID: 7527735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [M-VAC chemotherapy for patients with lymph node metastases and/or locally advanced bladder carcinoma].
    Igawa M; Ueki T; Ueda M; Okada K; Usui T; Ohnishi Y; Nakatsu H; Kume T; Kodama M; Masu C
    Hinyokika Kiyo; 1989 Aug; 35(8):1323-7. PubMed ID: 2683648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin for histologically proven lymph node positive bladder cancer.
    Nieuwenhuijzen JA; Bex A; Meinhardt W; Kerst JM; Schornagel JH; VAN Tinteren H; Horenblas S
    J Urol; 2005 Jul; 174(1):80-5. PubMed ID: 15947583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin-based neoadjuvant chemotherapy for invasive bladder cancer.
    Kadena H; Igawa M; Shigeta M; Nakamoto T; Usui T
    Hiroshima J Med Sci; 1995 Dec; 44(4):129-32. PubMed ID: 8857236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of cystectomy, and perioperative methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer.
    Ennis RD; Petrylak DP; Singh P; Bagiella E; O'Toole KM; Benson MC; Olsson CA
    J Urol; 2000 May; 163(5):1413-8. PubMed ID: 10751847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium.
    Dreicer R; Manola J; Roth BJ; See WA; Kuross S; Edelman MJ; Hudes GR; Wilding G
    Cancer; 2004 Apr; 100(8):1639-45. PubMed ID: 15073851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preliminary results of M-VAC chemotherapy combined with mild hyperthermia, a new therapeutic strategy for advanced or metastatic transitional cell carcinoma of the urothelium.
    Yamada Y; Itoh Y; Aoki S; Nakamura K; Taki T; Naruse K; Tobiume M; Zennami K; Katsuda R; Kato Y; Watanabe M; Nishikawa G; Minami M; Nakahira M; Ukai S; Sawada M; Kitamura A; Honda N
    Cancer Chemother Pharmacol; 2009 Nov; 64(6):1079-83. PubMed ID: 19277660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.